Antiviral Drugs Market Top Trends 2027 | Top Players F. Hoffmann-La Roche AG, GlaxoSmithKline plc, AbbVie, Johnson & Johnson

With extensive research and development activities as well as growing drug approvals, the antiviral drugs market is expected to procure commendable growth strides until 2027. There is a rise in the number of medical product approvals via collaborations and licensing worldwide. The occurrence of disease outbreaks such as Zika virus, Ebola virus and the coronavirus infections has driven the usage of antiviral drugs as a potential treatment.

There is a pressing need for continuous advancements and development in antiviral drugs, as viruses are quickly developing their structure against the environment and boosting their tolerance towards drugs. With the recent outbreak of COVID-19, governments are raising their funding capacity for pharmaceutical companies to make antiviral medications.

Request for a sample copy of this report @ https://www.gminsights.com/request-sample/detail/4968

Firms specializing in antiviral drugs are also focusing on new product development. For example, in 2020, Gilead Sciences announced FDA approval of its investigational antiviral drug, remdesivir, for emergency use in the treatment of COVID-19.

A report by Global Market Insights, Inc., states that the antiviral drugs market registered over USD 44 billion in 2020 and is projected to witness a -1.7% CAGR by 2027.

In terms of drug class, the reverse transcriptase inhibitors segment held over 40% of the industry share in 2020. Reverse transcriptase inhibitors are drug types which are classified as non-nucleoside reverse transcriptase inhibitors and nucleoside reverse transcriptase inhibitors (NRTI). Some of the drugs under the extensive portfolio of NNRTIs and NRTIs are Intelence, Atripla, Odefsey, Biktarvy, Descovy, and Complera, developed against retroviruses.

Surge in the launch of new generic medications could fare the prospects of generic antiviral drugs sector over the forecasted period. Generic antiviral drugs are being rapidly adopted for pre-exposure prophylaxis and treatment offering cost advantage to patients. Moreover, cost-effective generic versions of branded drugs raise treatment coverage due to less affordability of high cost drugs within middle and low income classes having less resources.

In terms of age group, the geriatric segment accounted for above 40% share in 2020 given to the high cost of treatment for elderly population and the prevalence of chronic diseases such as diabetes. The geriatric population is mostly vulnerable to infectious diseases and also is prone to high mortality especially since the coronavirus pandemic.

Request for customization @ https://www.gminsights.com/roc/4968

Companies develop antiviral drugs for such patient groups include Johnson & Johnson, AbbVie, Merck & Co., Gilead Sciences, AstraZeneca, and GlaxoSmithKline. These organizations are working on product innovations and partnerships, among others. In 2020, AstraZeneca announced its collaboration with several countries and multilateral organizations to make the University of Oxford’s vaccine extensively accessible across the globe in an equitable way.

Partial Chapter of the Table of Content

Chapter 4 Anti-viral Drugs Market, By Drug Class

4.1 Key segment trends

4.2 DNA polymerase inhibitors

4.2.1 Market size, by region, 2016 – 2027 (USD Million)

4.3 Reverse transcript inhibitors

4.3.1 Market size, by region, 2016 – 2027 (USD Million)

4.4 Protease inhibitors

4.4.1 Market size, by region, 2016 – 2027 (USD Million)

4.5 Neuraminidase Inhibitors

4.5.1 Market size, by region, 2016 – 2027 (USD Million)

4.6 Others

4.6.1 Market size, by region, 2016 – 2027 (USD Million)

Chapter 5 Anti-viral Drugs Market, By Indication

5.1 Key segment trends

5.2 Influenza

5.2.1 Market size, by region, 2016 – 2027 (USD Million)

5.3 HIV AIDS

5.3.1 Market size, by region, 2016 – 2027 (USD Million)

5.4 Hepatitis

5.4.1 Market size, by region, 2016 – 2027 (USD Million)

5.5 Herpes simplex virus (HSV)

5.5.1 Market size, by region, 2016 – 2027 (USD Million)

5.6 Coronavirus infection

5.6.1 Market size, by region, 2016 – 2027 (USD Million)

5.7 Others

5.7.1 Market size, by region, 2016 – 2027 (USD Million)

Browse full table of contents (TOC) of this report @ https://www.gminsights.com/toc/detail/antiviral-drugs-market

Contact Us:
Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com

About Global Market Insights, Inc.
Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy, and biotechnology.

This release was published on openPR.